-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Xcelerate, Inc. Announces Appointment of New Board Member
Xcelerate, Inc. Announces Appointment of New Board Member
MAULDIN, SC / ACCESSWIRE / May 11, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) recently announced that it had signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a company engaged in oncology research and the development of human and animal health care and medical products, as well as cosmetics and beauty products.
Today, the Company is pleased to announce that Mr. Jon Wilken, President and CEO of HS Pharmaceuticals is joining the Board of Directors of Xcelerate, Inc. Jon Wilken is a 30-year veteran of the retail food industry. He is the former President and CEO of BILO Inc., a supermarket chain which at the time of his employment was wholly owned by Ahold NV of The Netherlands. While Jon was at BILO, the company employed approximately 26,000 associates and operated over 400 retail supermarkets and convenience stores in four Southeastern States with annual sales of approximately $4.0 Billion. Since leaving Ahold/BILO in 2002 Jon has pursued entrepreneurial business ventures including partnering in a 250+ acre commercial and retail real estate planned development, The Point, in Greenville, South Carolina. The project to date has a Whole Foods supermarket, a retail shopping center, several restaurants, over 500 apartments, 8 hotels, and a 40-acre TD Bank call center campus.
"The Board and I welcome Jon and look forward to collaborating with him on the various projects and, more especially, assisting in assimilating the recently acquired patent portfolio into our business plan. Jon has spent years coordinating the development of these patents and coordinating the efforts of various research scientists and universities." said Xcelerate CEO Michael O'Shea. "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world renowned scientists and universities and we are excited to take this amazing intellectual property to the next level."
"I am looking forward to joining Mike and his team of health care and research professionals at XCRT. HS Pharma and its team of scientific and medical research professionals are committed to pursuing our promising researching in the fields of wound healing, oncology, bone regeneration, and autoimmune disorders, we are excited about the possibilities" commented Jon Wilken, President and CEO of HS Pharmaceuticals.
Vince Sordello, COO, HSP, will continue to monitor and maintain our patent (IP) portfolio and guide our research as we continue our quest for medical breakthrough science in wound healing, oncology, bone regeneration and autoimmune therapies.
About Xcelerate, Inc.
Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.
Xcelerate has also recently acquired a 51% ownership interest in AfiyaSasa Africa, LLC a start-up medical technology and virtual health company, recently founded by Dr. Dilan Ellegala and Doyle Word. This technology is centered around patented and patent pending software that uses and incorporates artificial intelligence ("AI") and Augmented Reality ("AR") licensed from AdviNOW.
For more information, visit the company's website at
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
Xcelerate Contact
Info@Xcelerate.Global
SOURCE: Xcelerate, Inc.
View source version on accesswire.com:
MAULDIN, SC / ACCESSWIRE / May 11, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) recently announced that it had signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a company engaged in oncology research and the development of human and animal health care and medical products, as well as cosmetics and beauty products.
南卡罗来纳州莫尔丁,ACCESSWIRE/2022年5月11日/Xcelerate公司(场外交易代码:XCRT)最近宣布,它已经签署了一项购买协议,从HS PharmPharmticals LLC收购一系列专利、正在申请的专利和技术许可证。HS PharmPharmticals LLC是一家从事肿瘤学研究和人类和动物保健、医疗产品以及化妆品和美容产品开发的公司。
Today, the Company is pleased to announce that Mr. Jon Wilken, President and CEO of HS Pharmaceuticals is joining the Board of Directors of Xcelerate, Inc. Jon Wilken is a 30-year veteran of the retail food industry. He is the former President and CEO of BILO Inc., a supermarket chain which at the time of his employment was wholly owned by Ahold NV of The Netherlands. While Jon was at BILO, the company employed approximately 26,000 associates and operated over 400 retail supermarkets and convenience stores in four Southeastern States with annual sales of approximately $4.0 Billion. Since leaving Ahold/BILO in 2002 Jon has pursued entrepreneurial business ventures including partnering in a 250+ acre commercial and retail real estate planned development, The Point, in Greenville, South Carolina. The project to date has a Whole Foods supermarket, a retail shopping center, several restaurants, over 500 apartments, 8 hotels, and a 40-acre TD Bank call center campus.
今天,公司高兴地宣布,HS制药公司总裁兼首席执行官乔恩·威尔肯先生将加入Xcelerate公司的董事会。乔恩·威尔肯是在零售食品行业工作了30年的资深人士。他是BILO公司的前总裁兼首席执行官,这是一家连锁超市,在他受雇时,该公司由荷兰的Ahold NV全资拥有。乔恩在BILO期间,该公司雇佣了大约26,000名员工,在东南部四个州经营着400多家零售超市和便利店,年销售额约为40亿美元。自2002年离开Ahold/Bilo以来,Jon一直致力于创业投资,包括合作开发南卡罗来纳州格林维尔一个250英亩以上的商业和零售房地产开发项目The Point。到目前为止,该项目已拥有一家全食超市、一个零售购物中心、几家餐厅、500多套公寓、8家酒店和一个占地40英亩的TD银行呼叫中心园区。
"The Board and I welcome Jon and look forward to collaborating with him on the various projects and, more especially, assisting in assimilating the recently acquired patent portfolio into our business plan. Jon has spent years coordinating the development of these patents and coordinating the efforts of various research scientists and universities." said Xcelerate CEO Michael O'Shea. "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world renowned scientists and universities and we are excited to take this amazing intellectual property to the next level."
董事会和我对乔恩表示欢迎,并期待着在各种项目上与他合作,尤其是帮助将最近收购的专利组合纳入我们的商业计划。乔恩多年来一直在协调这些专利的开发,并协调各种研究科学家和大学的努力。Xcelerate首席执行官迈克尔·奥谢说。在过去的10多年里,HS制药公司一直在与世界知名的科学家和大学一起管理这些专利,我们很高兴能将这一令人惊叹的知识产权提升到一个新的水平。“
"I am looking forward to joining Mike and his team of health care and research professionals at XCRT. HS Pharma and its team of scientific and medical research professionals are committed to pursuing our promising researching in the fields of wound healing, oncology, bone regeneration, and autoimmune disorders, we are excited about the possibilities" commented Jon Wilken, President and CEO of HS Pharmaceuticals.
HS制药公司总裁兼首席执行官乔恩·威尔肯评论说:“我期待着加入Mike和他的保健和研究专业团队。HS Pharma及其科学和医学研究专业团队致力于在伤口愈合、肿瘤学、骨再生和自身免疫性疾病领域进行我们前景光明的研究,我们对这些可能性感到兴奋。
Vince Sordello, COO, HSP, will continue to monitor and maintain our patent (IP) portfolio and guide our research as we continue our quest for medical breakthrough science in wound healing, oncology, bone regeneration and autoimmune therapies.
HSP首席运营官文斯·索德洛将继续监测和维护我们的专利(IP)组合,并指导我们的研究,因为我们继续在伤口愈合、肿瘤学、骨再生和自身免疫疗法方面寻求医学突破性科学。
About Xcelerate, Inc.
关于Xcelerate公司
Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.
Xcelerate是一家初创、处于发展阶段的公司,它组建了一个由国际知名的翻译临床医生和工程师组成的顾问委员会,以帮助公司识别和获取尖端工程技术进步和知识产权,其中大多数技术进步和知识产权在医疗技术和临床护理方面没有立即明显的应用。该公司的目标是在工程/专利层面获得创新,并开发医疗技术和临床护理应用。
Xcelerate has also recently acquired a 51% ownership interest in AfiyaSasa Africa, LLC a start-up medical technology and virtual health company, recently founded by Dr. Dilan Ellegala and Doyle Word. This technology is centered around patented and patent pending software that uses and incorporates artificial intelligence ("AI") and Augmented Reality ("AR") licensed from AdviNOW.
Xcelerate最近还收购了AfiyaSasa Africa LLC 51%的股权,AfiyaSasa Africa LLC是一家初创医疗技术和虚拟健康公司,最近由Dilan ElLegala博士和Doyle Word创建。这项技术以专利和正在申请专利的软件为中心,这些软件使用并整合了AdviNOW授权的人工智能(AI)和增强现实(AR)。
For more information, visit the company's website at
欲了解更多信息,请访问该公司网站:
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
Xcelerate Contact
安全港
本新闻稿可能包含经修订的1934年证券交易法(“交易法”)第21E节所指的前瞻性信息,包括与公司、其董事或高级管理人员在以下方面的意图、信念或当前预期有关的所有不是历史事实的陈述:(1)公司的融资计划;(2)影响公司财务状况或经营结果的趋势;(3)公司的增长战略和经营战略;以及(4)宣布和支付股息。“可能”、“将”、“将”、“预期”、“估计”、“预期”、“相信”、“打算”以及类似的表述及其变体旨在识别前瞻性陈述。请投资者注意,任何这样的前瞻性陈述都不是对未来业绩的保证,涉及风险和不确定因素,其中许多风险和不确定因素是公司无法控制的,由于各种因素,实际结果可能与前瞻性陈述中所预测的大不相同。
加速触点
Info@Xcelerate.Global
邮箱:Info@Xcelerate.Global
SOURCE: Xcelerate, Inc.
资料来源:Xcelerate公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧